Notably, ARAF has a significantly lower kinase activity than BRAF and CRAF, but its overexpression prolonged the duration of MAPK activation [11], potentially creating conditions conducive to tumor cell survival and the transcription of neuroendocrine markers in the presence of EGFR-TKIs. The gene discussed is BRAF; the disease is neoplasm.